Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) chief financial officer Eyal Desheh says the world’s largest generic drugmaker is open for deals as the pace of industry consolidation quickens.

“We do have an appetite for game-changing deals that will create value by doing the transaction and we’re willing to pursue them,” Desheh said yesterday at a Cowen & Company health-care conference, when asked about the “fragmented” market of neurology companies.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.